M.R. Consulting provides Strategic Consulting services to pharmaceutical and medical devices companies wishing to introduce their products in Israel.
M.R. Consulting provides consulting services in the field of Market Access, National Reimbursement processes and Pharmacoeconomics.
M.R. Consulting has a vast experience in bringing new medical products to the Israeli market while reducing the time-to-market for our customers.
The National Health Basket (NHB), defined by the National Health Insurance Law, is the main channel through which new drugs and medical technologies become available to the public via national funding in Israel. New drugs are added to the NHB in a yearly process to which special budget is allocated by the government. This budget might change from year to year. In the last several years its magnitude was 300M NIS (63.5M €). Each year, drugs and medical technologies worth of more than 2B NIS are submitted for NHB inclusion, thus compete on the allocated budget.
The NHB Public Committee is comprised of 18 representatives of several disciplines (physicians, health economists, public representatives) and backgrounds across the society. Its duty is to recommend on the NHB inclusion of those drugs and technologies that would maximize public’s benefit within the framework of the predetermined budget. Thus, Ministry of Health and the Committee are looking for the best methodology to prioritize the drugs and technologies submitted, in order to achieve this objective.
Pharmaceutical and medical devices manufacturing and importing companies submitting their products for inclusion in the NHB, have to build a comprehensive and convincing dossier for the reimbursement authorities that would include detailed information on the clinical benefit of the product, present a reasonable budget-impact analysis and convince NHB Committee that the product’s cost-effectiveness ratio justifies its preference over other submitted products, and that its inclusion in the NHB would meet the objective of maximizing public’s health. If the NHB Committee members and/or other key decision makers (HMOs, hospitals, Ministry of Health officials) are convinced of that, then they will prioritize the submitted product higher than other submitted products, which will in turn increase its chances for inclusion in the NHB and receiving national reimbursement.
Additional paths for reimbursement for medical products include complementary insurance programs within the HMOs (Sick Funds), private health insurance programs and hospital formularies.
